Arrest Oral Suspension

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Fenbendazole; Levamisole hydrochloride

Available from:

Ancare Ireland Ltd.

ATC code:

QP52AC13; QP52AE01

INN (International Name):

Fenbendazole; Levamisole hydrochloride

Dosage:

2.50/3.75 percent weight/volume

Pharmaceutical form:

Oral suspension

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Sheep

Therapeutic area:

fenbendazole; levamisole

Therapeutic indications:

Endoparasiticide

Authorization status:

Authorised

Authorization date:

2001-01-26

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Arrest Oral Suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of roundworm, lungworm and tapeworm infections of
sheep caused by:
Gastrointestinal Roundworms:_ Bunostomum, Chabertia, Cooperia,
Haemonchus, Nematodirus, Oesophagostomum,_
_Ostertagia, Trichostrongylus_
Lungworms:
_Dictyocaulus_
Tapeworm:
_Moniezia_ spp
The product is active against mature and immature parasite stages
sensitive to fenbendazole or levamisole.
Fenbendazole is ovicidal and will kill worm eggs.
4.3 CONTRAINDICATIONS
Do not use in animals that are severely stressed or in ill-health.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not administer to sheep under stress or in poor condition.
Active Substance
Levamisole Hydrochloride
3.75 % w/v
Fenbendazole
2.50 % w/v
Excipients
Formaldehyde Solution
0.20 % w/v
Potassium Sorbate
0.18 % w/v
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_3_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_3_
_1_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
Assess bodyweight as accurately as possible before calculating dosage
recommended.
Do not exceed dose rates. Intensive use or misuse of anthelmintics can
give rise to resistanc